Infinity will not go beyond Phase II with retaspimycin
This article was originally published in Scrip
Infinity Pharmaceuticals ended development for its selective heat shock protein 90 (Hsp90) inhibitor retaspimycin hydrochloride following a failed Phase II lung cancer study and will focus instead on IPI-145, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma.
You may also be interested in...
Infinity's hopes for accelerated approval of duvelisib based on the DYNAMO study have been dashed, so as the company plots a new strategy for the PI3K inhibitor – with or without its partner AbbVie – it has cut discovery research operations, including 46 jobs.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.